• PSS3 THE ECONOMIC IMPACT OF DRY EYE DISEASE IN THE UNITED STATES

    May 1, 2010, 00:00

  • PMH45 DAILY AVERAGE CONSUMPTION AND PHARMACY COSTS OF DULOXETINE ACROSS MULTIPLE INDICATIONS AMONG COMMERCIALLY INSURED PATIENTS

    May 1, 2010, 00:00

  • PMC1 EVALUATING CLINICIAN REPORTED OUTCOME (CRO) ENDPOINTS FOR FDA REGULATORY APPROVALS

    May 1, 2010, 00:00

  • PND41 THE EFFECT OF MULTIPLE COMPARISONS ADJUSTMENTS IN ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE BY WORK STATUS

    May 1, 2010, 00:00

  • PDB69 OLDER PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES (T2DM) EXPERIENCE MORE DELAYED TREATMENT WITH ORAL ANTIHYPERGLYCEMIC AGENTS COMPARED WITH YOUNGER PATIENTS

    May 1, 2010, 00:00

  • PHP46 THE FINANCIAL IMPACT OF MEDICATION RECONCILIATION TO REDUCE DRUG-RELATED PROBLEMS

    May 1, 2010, 00:00

  • PMS76 DERIVING SEVERITY INDEX FOR RHEUMATOID ARTHRITIS FROM HEALTH CARE CLAIMS DATA

    May 1, 2010, 00:00

  • PMS74 USE OF A DISEASE-SPECIFIC INSTRUMENT IN ECONOMIC EVALUATIONS- MAPPING WOMAC ONTO THE EQ-5D UTILITY INDEX

    May 1, 2010, 00:00

  • PCN136 THE IMPACT OF PROSTATE CANCER AMONG CAUCASIAN AND AFRICAN AMERICANS IN A HOSPITALIZED SETTING

    May 1, 2010, 00:00

  • PCN7 A COMPARISON OF INTRAVENOUS AND ORAL FORMULATIONS OF FLUDARABINE IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

    May 1, 2010, 00:00

  • PDB32 ECONOMIC AND HEALTH CONSEQUENCES OF THE USE OF A DPP4 PLUS METPHORMINE SCHEME IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN MEXICO FROM THE PRIVATE PERSPECTIVE

    May 1, 2010, 00:00

  • PHP98 THE ROLE OF AUTHORIZED GENERICS IN THE PRESCRIPTION DRUG MARKETPLACE

    May 1, 2010, 00:00

  • PHP73 IMPACT OF PHARMACEUTICAL REFORM AND ISSUES INVOLVED IN SOUTH KOREAS NHI

    May 1, 2010, 00:00

  • PHP10 COST CONSEQUENCE ANALYSIS OF PRESCRIPTION DRUG LABEL CHANGES

    May 1, 2010, 00:00

  • PHP60 RATIONAL USE EFFECTS OF IMPLEMENTING AN ESSENTIAL MEDICINES LIST

    May 1, 2010, 00:00

  • PCN141 USING A DISEASE MANAGEMENT APPROACH IN A HEALTH TECHNOLOGY ASSESSMENT- A CASE STUDY

    May 1, 2010, 00:00

  • PIN41 UNDERSTANDING CHILDRENS PREFERENCES FOR INFLUENZA VACCINES USING CONJOINT ANALYSIS

    May 1, 2010, 00:00

  • PRS10 INCIDENCE RATE AND MAJOR CAUSES OF PROLONGED MECHANICAL VENTILATION IN TAIWAN- A POPULATION-BASED STUDY DURING 1997-2007

    May 1, 2010, 00:00

  • PSY1 CONCORDANCE IN PATIENT REPORTED MEASURES OF OPIOID-RELATED SIDE EFFECTS COLLECTED FROM CHECKLIST VERSUS OPEN-TEXT FORMAT QUESTIONS

    May 1, 2010, 00:00

  • PSS1 BEVACIZUMAB FOR NEO-VASCULAR AGE RELATED MACULAR DEGENERATION-EVIDENCE SUMMARY

    May 1, 2010, 00:00

  • PMH68 A LONGITUDINAL ANALYSIS OF THE EFFECT OF BUPRENORPHINE-MEDICATION ASSISTED TREATMENT (B-MAT) AND A STRUCTURED PATIENT SUPPORT PROGRAM ON B-MAT ADHERENCE IN A NATIONAL SAMPLE OF OPIOID DEPENDENT PATIENTS

    May 1, 2010, 00:00

  • PMH53 ESTIMATION OF UTILITY GAINED FROM METHADONE MAINTENANCE TREATMENT FOR OPIOID DEPENDENCE

    May 1, 2010, 00:00

  • PCN158 A METHOD TO INCREASE SAMPLE SIZE BY REMOVING THE CONTINUOUS ENROLLMENT REQUIREMENT

    May 1, 2010, 00:00

  • PMC8 THE EFFECT OF LENGTH OF OBSERVATION AND CLAIMS DATA TYPE ON ESTIMATES OF COMORBIDITIES AMONG MEDICAID BENEFICIARIES

    May 1, 2010, 00:00

  • PSY44 DAILY ASSESSMENT OF OUTCOMES CAPTURING HOME TREATMENT OF CONGENITAL HEMOPHILIA WITH INHIBITORS (CHWI)- DESIGN, DISPOSITION AND IMPLICATIONS OF THE DOSING OBSERVATIONAL STUDY IN HEMOPHILIA (DOSE)

    May 1, 2010, 00:00

  • PCN29 REAL WORLD DATA ON MULTIFRACTION (MFR) VERSUS SINGLE FRACTION (SFR) RADIOTHERAPY TO TREAT BONE METASTASIS- IMPACT IN COSTS FOR PRIVATE HEALTH CARE (PHC) PROVIDERS IN BRAZIL

    May 1, 2010, 00:00

  • PMS21 COST-EFFECTIVENESS OF RITUXIMAB VS ADALIMUMAB IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS

    May 1, 2010, 00:00

  • PCN122 HPV VACCINE COVERAGE AND ADOPTION ACROSS THE UNITED STATES

    May 1, 2010, 00:00

  • PCV89 COST EFFECTIVENESS OF PRASAGREL OR CHOPIDOGREL FOR TREATMENT OF ACS PATIENTS BASED ON GENETIC TESTING FOR CYP2C19 VARIANTS

    May 1, 2010, 00:00

  • PMS56 ACCESS TO BIOLOGIC TREATMENT IN RHEUMATOID ARTHRITIS IN CENTRAL AND EASTERN EUROPEAN (CEE) COUNTRIES

    May 1, 2010, 00:00

  • PMS45 ASSESSING HEALTH-RELATED QUALITY OF LIFE IN TAIWANESE RHEUMATOID ARTHRITIS PATIENTS BY APPLYING TIME-TRADE-OFF AND EQ-5D METHODS

    May 1, 2010, 00:00

  • PHP61 WILLINGNESS TO PAY FOR PHARMACY SERVICES- A REVIEW

    May 1, 2010, 00:00

  • PGI31 PAIN AFTER LIVER TRANSPLANT- A CROSS SECTIONAL STUDY

    May 1, 2010, 00:00

  • PCV35 SEASONAL VARIATION AND INFLUENCE OF METEOROLOGICAL FACTORS IN CASE OF ACUTE CEREBROVASCULAR EVENTS

    May 1, 2010, 00:00

  • PIN46 FACTORS ASSOCIATED WITH SUBOPTIMAL ADHERENCE TO HUMAN IMMUNODEFICIENCY VIRUS THERAPY

    May 1, 2010, 00:00

  • PCN53 RETROSPECTIVE US CLAIMS DATABASE ANALYSIS OF THE COST OF SEQUENCING OF SORAFENIB AND SUNITINIB IN THE TREATMENT OF PATIENTS WITH RENAL CELL CARCINOMA (RCC)

    May 1, 2010, 00:00

  • PCV101 THE IMPACT OF MULTIPLE CARDIOVASCULAR DIEASES ON ANTIDIABETIC MEDICATION ADHERENCE IN A CALIFORNIA MEDICAID POPULATION WITH COMORBID TYPE II DIABETES AND CARDIOVASCULAR DISEASE

    May 1, 2010, 00:00

  • PMS51 PRESCRIPTION PATTERNS AND EXPENDITURE OF ANTI-TNG AGENTS IN RHEUMATOID PATIENTS IN TAIWAN

    May 1, 2010, 00:00

  • PMH7 TRENDS AND PATTERNS IN THE DIAGNOSIS AND PRESCRIBING OF PSYCHOTROPIC MEDICATIONS IN CHILDREN AND ADOLESCENTS WITH ADHD.

    May 1, 2010, 00:00

  • PDB11 RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH DIABETES TREATED WITH EXENATIDE OR THIAZOLIDINEDIONES- A RETROSPECTIVE ANALYSIS OF THE PHARMETRICS DATABASE

    May 1, 2010, 00:00

  • PUK20 ECONOMIC EVALUATION OF THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA IN COLOMBIA

    May 1, 2010, 00:00

  • PSS15 COMPARISON OF THE PRO ENDPOINTS FOUND IN LABELING CLAIMS OF PRODUCTS FOR THE TREATMENT OF PSORIASIS WITH THOSE RECOMMENDED BY THE CORRESPONDING EMEA GUIDANCE

    May 1, 2010, 00:00

  • PDB1 ASSOCIATION BETWEEN GLYCOSYLATED HEMOGLOBIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS- A NESTED CASE-CONTROL STUDY

    May 1, 2010, 00:00

  • PMS1 ASSESSMENT OF COMORBIDITIES IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA)-FINDINGS FROM A RETROSPECTIVE CLAIMS DATABASE ANALYSIS USING A PRE-PROGRAMMED DATA ANALYSIS TOOL

    May 1, 2010, 00:00

  • PND29 AN ASSESSMENT OF DISEASE-SPECIFIC HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS RELATING TO BLADDER DYSFUNCTION USED IN PATIENTS WITH MULTIPLE SCLEROSIS

    May 1, 2010, 00:00

  • PCN125 NUMBER OF DOCETAXEL TREATMENT CYCLES AND OVERALL SURVIVAL FOR METASTATIC PROSTATE CANCER-RESULTS FROM A US LOCAL COMMUNICTY PRACTICE

    May 1, 2010, 00:00

  • PMH85 IMPACT OF FDA ANTIDEPRESSANT BLACK BOX WARNING AND OTHER REGULATORY CHANGES ON PRESCRIPTION PATTERN FOR CHILDREN BY OFFICE BASED PHYSICIANS USING NATIONAL AMBULATORY MEDICAL CARE SURVEY (NAMCS)

    May 1, 2010, 00:00

  • PCN75 COST-EFFECTIVENESS ANALYSIS OF EGFR MUTATION TESTING IN PATIENTS WITH ADVANCED NON SMALL-CELL LUNG CANCER (ANSCLC) TREATED WITH GEFITINIB OR CARBOPLATIN-PACLITAXEL

    May 1, 2010, 00:00

  • PMC12 RULING OUT EXTENDLY DOMINATED OPTIONS USING AN ICER MATRIX

    May 1, 2010, 00:00

  • PMH92 TIME SERIES ANALYSIS TO EXAMINE THE EFFECT OF GUIDELINES

    May 1, 2010, 00:00

  • PCV140 UNDERSTANDING THE CURRENT LIPID PROFILE, TREATMENT, AND CASE MIX OF PATIENTS WITH DYSLIPIDEMIA IN A REAL-WORLD POPULATION

    May 1, 2010, 00:00

  • PCN52 HEALTH CARE COSTS ASSOCIATED WITH MULTIKINASE INHIBITORS (MKIS) FOR TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) IN A CLINICAL PRACTICE SETTING IN ITALY

    May 1, 2010, 00:00

  • PMS30 ADHERENCE TO DULOXETINE AND HOSPITAL UTILIZATION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND CHRONIC PAIN

    May 1, 2010, 00:00

  • PCN116 PILOT STUDY FOR EVULATION OF OUTCOMES OF BREAST CANCER WITH SPECIAL FOCUS ON ECONOMIC IMPACT AND QUALITY OF LIFE

    May 1, 2010, 00:00

  • PCN91 VALIDATION OF HEALTH OUTCOMES RESEARCH OF CANCER

    May 1, 2010, 00:00

  • PIN43 MENINGITIS VACCINE COVERAGE AND ADOPTION ACROSS THE UNITED STATES

    May 1, 2010, 00:00

  • PMC11 CAP DATABASE-PROVISION OF OUTPATIENT PROCEDURE DATA IN A UNIFIED, STANDARDIZED LANGUAGE

    May 1, 2010, 00:00

  • PIN42 DRG-BASED HOSPITAL PAYMENT SYSTEM IMPACT ON MEDICAL DECISION MAKING

    May 1, 2010, 00:00

  • PUK11 COST-EFFECTIVENESS ANALYSIS OF DUTASTERIDE, TAMSULOSIN AND COMBINATION THERAPY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

    May 1, 2010, 00:00

  • PCV51 AN ASSESSMENT OF DIRECT COSTS OF SINGLE PILL VERSUS FREE COMBINATION ARB/CCB THERAPY IN PATIENTS WITH HYPERTENSION

    May 1, 2010, 00:00

  • DB1 DEVELOPMENT AND VALIDATION OF A MODEL TO PREDICT VIROLOGIC FAILURE USING ADMINISTRATIVE CLAIMS

    May 1, 2010, 00:00

  • PUK21 POST-KIDNEY TRANSPLANT MORBIDITY RELATED RE-HOSPITALIZATIONS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM- CAUSES, RESOURCES USE AND COSTS BASED ON AN ADMINISTRATIVE REGISTRY REVIEW FROM 2004 TO 2009

    May 1, 2010, 00:00

  • PMS60 UTILIZING HEALTH SURVEY AND ADMINISTRATIVE DATA TO ESTIMATE THE BURDEN OF OSTEO-ARTHRITIS IN ONTARIO

    May 1, 2010, 00:00

  • PMH2 PATTERNS IN PRESCRIPTIONS OF ANTISYPCHOTICS FOR PATIENTS WITH MOOD DISORDERS AND THEIR OUTCOMES

    May 1, 2010, 00:00

  • PIN22 COST-EFFECTIVENESS ANALYSIS OF LINEZOLID VS VANCOMYCIN IN EMPIRIC TREATING MECHANIC VENTILATION-ASSOCIATED PNEUMONIA BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (VAP-MRSA) IN COLOMBIA

    May 1, 2010, 00:00

  • CASE1 IMPLEMENTATION OF A NONFORMULARY PRESCRIBING MONITORING SYSTEMS REVEALS OPPORTUNITIES FOR COST SAVINGS IN AN ACADEMIC MEDICAL CENTER

    May 1, 2010, 00:00

  • PCN95 COST-EFFECTIVENESS OF SEROTONIN-TYPE 3 RECEPTOR ANTAGONISTS FOR CHEMOTHERAPY-INDUCED EMESIS IN NON SMALL CELL LUNG CANCER PATIENTS RECEIVING CISPLATIN-BASED CHEMOTHERAPY

    May 1, 2010, 00:00

  • PIN15 COST-EFFECTIVENESS OF THREE CARBAPENEMIC ANTI-INFECTIVES FOR TREATMENT OF VENTILATOR-ASSOCIATED PNEUMONIA (VAP) IN COLOMBIA

    May 1, 2010, 00:00

  • PHP104 THE BUDGET IMPACT OF ORAL NUTRITIONAL SUPPLEMENTS IN THE COMMUNITY SETTING IN THE NETHERLANDS

    May 1, 2010, 00:00

  • PHP50 DRUGS CHEAPER THAN THREEPENNY- THE MARKET OF EXTREMELY LOW-PRIZED DRUGS WITHIN THE NATONAL HEALTH INSURANCE IN TAIWAN

    May 1, 2010, 00:00

  • PUK14 CHALLENGES IN ASSESSING COST-EFFECTIVENESS OF THERAPIES FOR DIALYSIS PATIENTS- A CASE STUDY OF SEVELAMER FOR THE TREATMENT OF HYPERPHOSPHATEMIA

    May 1, 2010, 00:00

  • PDB46 ADHERENCE TO STATIN THERAPY AMONG THE DIABETES PATIENTS AT A SELF-INSURED MID-WESTERN UNIVERSITY IN THE UNITED STATES

    May 1, 2010, 00:00

  • PCV108 PATTERNS AND PREDICTORS OF PERSISTENCE OF WARFARIN AND OTHER COMMONLY-UTILIZED CHRONIC MEDICATIONS AMONG PATIENTS WITH ATRIAL FIBRILLATION

    May 1, 2010, 00:00

  • PHP107 THE HEALTH ECONOMIC IMPACT OF ORAL NUTRITIONAL SUPPLEMENTS IN THE HOSPITAL SETTING IN GERMANY

    May 1, 2010, 00:00

  • PCN155 TREATMENT PATTERN OF METASTATIC TRIPLE NEGATIVE BREAST CANCER IN COMMUNITY PRACTICE

    May 1, 2010, 00:00

  • PCN114 EXPLORING THE BURDEN OF ILLNESS ON NEWLY DIAGNOSED ESOPHAGEAL CANCER PATIENTS IN TAIWAN -PRELIMINARY ANALYSIS

    May 1, 2010, 00:00

  • PMC32 PATIENT SATISFACTION COMPARISONS BETWEEN PEDIATRICIANS AND OTHER PCPS- A MULTILEVEL CROSS-NATIONAL WEB BASED SURVEY STUDY

    May 1, 2010, 00:00

  • PSY2 PREDICTORS OF OBESITY MEDICATION USE IN AMBULATORY SETTING- NAMCS 2006-07 ANALYSIS

    May 1, 2010, 00:00

  • PCN71 COST EFFECTIVENESS ANALYSIS OF BREAST CANCER RISK REDUCTION THERAPY- COMPARING TAMOXIFEN AND RALOXIFENE

    May 1, 2010, 00:00

  • PDB51 THE IMPACT OF NON-SEVERE HYPOGLYCEMIC EPISODES ON WORK PRODUCTIVITY AND DIABETES MANAGEMENT- A FOUR COUNTRY PERSPECTIVE

    May 1, 2010, 00:00

  • PCN154 COLORECTAL CANCER HOSPITAL ADMISSIONS IN WEST VIRGINIA FROM 2003 TO 2007

    May 1, 2010, 00:00

  • PIN12 THE COST OF TUBERCULOSIS CONTROL IN THE ADULT POPULATION OF THE REPUBLIC OF ARMENIA, 2006

    May 1, 2010, 00:00

  • PCN156 IMPROVING ASCERTAINMENT OF VITAL STATUS USING SOCIAL SECURITY DEATH MASTER FILE (SSDMF) AND THE NATIONAL DEATH INDEX (NDI)

    May 1, 2010, 00:00

  • PDB36 ASSESSING THE IMPACT OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR POST-HERPETIC NEURALGIA (PHN) RELATED HEALTH IMPAIRMENT ON LOSS OF PRODUCTIVE TIME (LOPT)

    May 1, 2010, 00:00

  • PCN128 SOCIAL DISPARITIES ACROSS THE CONTINUUM OF LUNG CANCER- A SYSTEMATIC REVIEW OF THE LITERATURE

    May 1, 2010, 00:00

  • PCASE2 DEVELOPING CRITERIA FOR USE FOR CONTINUOUS GLUCOSE MONITORING (CGM) SENSORS IN A VETERAN POPULATION

    May 1, 2010, 00:00

  • PMH56 ADULT ATTENTION DEFICIT HYPERACTIVITY DISORDER, LABOR FORCE STATUS AND WORKPLACE ABSENTEEISM AND PRESENTEEISM

    May 1, 2010, 00:00

  • PMH3 DESCRIPTIVE UNDERSTANDING OF DIAGNOSED OPIOID MISUSERS VERSUS OTHER OPIOID USERS

    May 1, 2010, 00:00

  • PMS35 ASSESSING THE EQUIVALENCE OF ELECTRONIC AND PAPER DATA COLLECTION OF EQ-5D DATA IN RHEUMATOID ARTHRITIS

    May 1, 2010, 00:00

  • PDB70 EVALUATION OF SITAGLIPTIN DOSING AMONG RENAL IMPAIRED TYPE 2 DIABETES MELLITUS PATIENTS

    May 1, 2010, 00:00

  • PHP70 ARE GOVERNMENT BASED REIMBURSEMENT PROGRAMS PERCEIVED BETTER OR WORSE COMPARED TO COMMERCIAL MANAGED CARE INSURANCE PAYERS BY PHARMACISTS?

    May 1, 2010, 00:00

  • CN2 USE OF LATENT VARIABLE AND SURVIVAL MODELING TO ESTIMATE THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES AND PROGRESSION-FREE SURVIVAL IN MALIGNANT PLEURAL MESOTHELIOMA

    May 1, 2010, 00:00

  • PCV66 COSTS ASSOCIATED WITH DISCHARGES AGAINST MEDICAL ADVICE IN A CVD POPULATION

    May 1, 2010, 00:00

  • PND32 ANALYSIS OF DULOXETINE UTILIZATION AMONG COMMERCIALLY-INSURED FIBROMYALGIA PATIENTS

    May 1, 2010, 00:00

  • PCV5 ADVERSE EVENT ANALYSIS FOR MEDICARE PATIENTS WHO UNDERWENT HIP FRACTURE SURGERY AND SUFFERED VENOUS THROMBOEMBOLISM

    May 1, 2010, 00:00

  • PMH81 ANTIPSYCHOTIC USE IN SENIORS- AN ANALYSIS FOCUSING ON DRUG CLAIMS FROM 2001 TO 2007

    May 1, 2010, 00:00

  • PCN36 COST OF ILLNESS FOR PATIENTS WITH METASTATIC COLORECTAL CANCER

    May 1, 2010, 00:00

  • PRS28 COST-UTILITY ANALYSES OF DISEASE-MODIFYING THERAPIES FOR PATIENTS WITH RELAPSE-REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATE

    May 1, 2010, 00:00

  • PMS26 COSTS OF VERTEBROPLASTY AND KYPHOPLASTY FROM THE HOSPITAL PERSPECTIVE

    May 1, 2010, 00:00

  • PDB64 USING DECISION MODELING TO DETERMINE COST-EFFECTIVENESS OF PHARMACIST INTERVENTIONS FOR PATIENTS WITH DIABETES

    May 1, 2010, 00:00

  • PMC16 REVIEW OF COST EFFECTIVENESS STUDIES OF HIGH BUDGET IMPACT DRUGS

    May 1, 2010, 00:00

  • PCV83 ECONOMIC ANALYSIS OF ENDOVASCULAR STENTING FOR PERIPHERAL ARTERIAL DISEASE IN LONG LESIONS OF THE SUPERFICIAL FEMORAL ARTERY

    May 1, 2010, 00:00

  • PSS4 COST EFFECTIVENESS ANALYSIS OF THE ACRYSOF CACHET PHAKIC INTRAOCULAR LENS

    May 1, 2010, 00:00

  • PMH38 SOCIETAL COSTS OF OPIOID ABUSE, DEPENDENCE, AND MISUSE IN THE UNITED STATES

    May 1, 2010, 00:00

  • PCV26 THROMBOPROPHYLAXIS OF PATIENTS RECEIVING TOTAL HIP REPLACEMENT- 1998-2002 VERSUS 2003-2007

    May 1, 2010, 00:00

  • PCV41 A DECADE OF STATIN LABORATORY TEST MONITORING IN THE UNITED STATES (1997-2007)- A COHORT STUDY

    May 1, 2010, 00:00

  • PMS58 HEALTH STATUS, PHYSICIAN, DAY PROCEDURES AND HOPITALIZATION COSTS ASSOCIATED WITH RHEUMATOID-ARTHRITIS IN ONTARIO

    May 1, 2010, 00:00

  • PIH17 COST-EFFECTIVENESS ANALYSIS OF FOUR EMBRYO TRANSFER STRATEGIES

    May 1, 2010, 00:00

  • PHP6 QUANTITATIVE ANALYSIS OF THE INFLUENCE OF DISEASE AND PRODUCT CHARACTERISTICS ON ORPHAN DRUG PRICES IN EUROPE

    May 1, 2010, 00:00

  • PRS27 COST-UTILITY ANALYSIS OF ANTI-SMOKING TREATMENTS

    May 1, 2010, 00:00

  • PCN146 REAL WORLD DATA ON MULTIPLE MYELOMA (MM) TREATMENT IN BRAZIL- GUIDANCE FOR THE PRIVATE HEALTH CARE SYSTEM (PHS)

    May 1, 2010, 00:00

  • PRS40 THE IMPACT OF THE FDAS RISK EVALUATION AND MITIGATION STRATEGIES (REMS) INITIATIVE ON PRESCRIPTION PATTERN FOR DRUGS APPROVED UNDER THE REMS PROGRAM AND RELEVANT NON-REMS COMPETITORS

    May 1, 2010, 00:00

  • PMH15 PREDICTORS OF FAVORABLE LONG-TERM OUTCOME IN THE TREATMENT OF SCHIZOPHRENIA

    May 1, 2010, 00:00

  • PGI35 PROTON PUMP INHIBITOR USE IN SENIORS- AN ANALYSIS FOCUSING ON DRUG CLAIMS 2001 TO 2008

    May 1, 2010, 00:00

  • PRS23 THE POTENTIAL COST IMPACT OF USING A PEG HYDROGEL SEALANT TO PREVENT AIR LEAKS AFTER LUNG RESECTION SURGERY IN THE UNITED KINGDOM

    May 1, 2010, 00:00

  • PCV75 ROBUST UNIVARIATE AND MULTIVARIATE SENSITIVITY ANALYSIS CONFIRM THAT ENOXAPARIN IS COST-SAVING TO THE PAYERS COMPARED WITH UFH FOR VTE PREVENTION IN PATIENTS WITH ISCHEMIC STROKE- ANALYSIS OF THE PREVAIL DATA

    May 1, 2010, 00:00

  • PCN27 ESTIMATED IMPACT OF EVEROLIMUS ON ANNUAL DRUG EXPENDITURE IN THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN A US HEALTH PLAN

    May 1, 2010, 00:00

  • PIN36 THE IMPACT OF AGE DEPENDENT UTILITY ON THE COST EFFECTIVENESS OF PEGYLATED INTERFERON AND RIBAVIRIN VERSUS INTERFERON AND RIBAVIRIN AS THERAPY FOR GENOTYPE I PATIENTS WITH CHRONIC HEPATITIS C

    May 1, 2010, 00:00

  • PGI24 COST UTILITY ANALYSIS OF CERTOLIZUMAB PEGOL VERSUS NATALIZUMB MAINTENANCE THERAPY FOR CROHNS DISEASE

    May 1, 2010, 00:00

  • DB4 ACCOUNTING FOR THE RELATIONSHIP BETWEEN PER DIEM COST AND LOS WHEN ESTIMATING HOSPITALIZATION COSTS

    May 1, 2010, 00:00

  • PCN103 A REVIEW AND META-ANALYSIS OF COLORECTAL CANCER UTILITIES

    May 1, 2010, 00:00

  • PSS7 COMPARING FIXED-COMBINATION THERAPIES FOR TREATING PATIENTS WITH OPEN-ANGLE GLAUCOMA IN A MANAGED CARE ENVIRONMENT

    May 1, 2010, 00:00

  • PHP41 USE OF ECONOMIC EVIDENCE IN PHARMACEUTICAL MARKETING AUTHORIZATION PROCEDURES, FIRST EXPERIENCE FROM IRAN

    May 1, 2010, 00:00

  • PCN131 THE COST OF TREATING LUNG CANCER IN THE UNITED STATES- AN ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY

    May 1, 2010, 00:00

  • PHP25 ASSESSING TRENDS IN UTILIZATION AND COST OF THE SIX PROTECTED MEDICATION CLASSES IN THE PART D PROGRAM

    May 1, 2010, 00:00

  • PGI1 ASSOCIATION OF WARFARIN, NSAIDS, AND GASTROINTESTINAL BLEED

    May 1, 2010, 00:00

  • PMH63 EVALUATING PATIENT ADHERENCE TO ANTIDEPRESSANT THERAPY AMONG UNINSURED WORKING ADULTS DIAGNOSED WITH MAJOR DEPRESSION- 12-MONTH RESULTS FROM THE TEXAS DEMONSTRATION TO MAINTAIN INDEPENDENCE AND EMPLOYMENT (DMIE) STUDY

    May 1, 2010, 00:00

  • PCN101 INPATIENT RESOURCE UTILIZATION IN BRONCHIAL AND LUNG CANCER- ANALYSIS OF 2007 HEALTH CARE UTILIZATION AND PROJECT (HCUP) DATA

    May 1, 2010, 00:00

  • PIH18 ANALYSIS OF NECROTIZING ENTEROCOLITIS COSTS AMONG EXTREMELY PRETERM INFANTS FED EXCLUSIVELY HUMAN-MILK BASED DIET VS. HUMAN-MILK FORTIFIED WITH BOVINE-MILK BASED SUPPLEMENTS

    May 1, 2010, 00:00

  • PCN35 OUT OF POCKET EXPENSES FOR BREAST CANCER SURVIVORS- DIFFERENCES BY TIME SINCE DIAGNOSIS IN A RURAL POPULATION

    May 1, 2010, 00:00

  • PIN18 COST-EFFECTIVENESS OF UNIVERSAL INFLUENZA VACCINATION IN THE US

    May 1, 2010, 00:00

  • PSY4 DAILY AVERAGE CONSUMPTION ANALYSIS OF LOW BACK PAIN AND OSTEOARTHRITIS PATIENTS USING OXYMORPHONE EXTENDED RELEASE AND OXYCODONE HYDORCHLORIDE CONTROLLED RELEASE TABLETS IN A COMMERCIALLY INSURED POPULATION

    May 1, 2010, 00:00

  • PCN109 DEVELOPMENT OF THE PATIENT-REPORTED VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE)

    May 1, 2010, 00:00

  • PCN80 A SYSTEMIC REVIEW OF COST-EFFECTIVENESS OF PROSTATESPECIFIC ANTIGEN (PSA) IN PROSTATE CANCER SCREENING

    May 1, 2010, 00:00

  • PMH66 REASONS FOR CONTINUING OR DISCONTINUING OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA FROM PATIENTS PERSPECTIVES

    May 1, 2010, 00:00

  • PDB44 A SYSTEMATIC REVIEW OF ADHERENCE, QUALITY OF LIFE AND MEDICAL COSTS IN FIXED-DOSE COMBINATION REGIMENS IN DIABETES

    May 1, 2010, 00:00

  • PCV11 IDENTIFYING RISK FACTORS ASSOCIATED WITH DISEASE BURDEN IN PATIENTS WITH TYPE II DIABETES AND COMORBID CARDIOVASCULAR DISEASE

    May 1, 2010, 00:00

  • PSY47 OBESITY- AND WEIGHT-SPECIFIC HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS FOR OBESE CHILDREN AND ADOLESCENTS

    May 1, 2010, 00:00

  • PHP37 THE USE OF COMPARATIVE EFFECTIVENESS INFORMATION BY FORMULARY DECISION-MAKERS

    May 1, 2010, 00:00

  • PND36 POTENTIAL BARRIERS TO HOME CARE USE AMONG PATIENTS WITH MULTIPLE SCLEROSIS

    May 1, 2010, 00:00

  • PCV111 ANALYZING THE RELATIONSHIP BETWEEN CHANGES IN PROS AND CLINICAL ENDPOINTS

    May 1, 2010, 00:00

  • PCV42 INPATIENT MORTALITY AND HOSPITALIZATION COSTS IN ATRIAL FIBRILLATION PATIENTS

    May 1, 2010, 00:00

  • PSS10 COST PER RESPONDER OF USTEKINUMAB VERSUS ETANERCEPT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS- ANALYSIS FROM THE ACCEPT TRIAL

    May 1, 2010, 00:00

  • PCV53 ALISKIREN COMBINED WITH ANGIOTENSIN II-RECEPTOR BLOCKERS (ARB) RESULTED IN BETTER OUTCOMES COMPARED TO ARB COMBINED WITH ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACEI)- RESULTS FROM A CLAIMS DATABASE ANALYSIS

    May 1, 2010, 00:00

  • PCV23 REDUCTIONS IN CORONARY HEART DISEASE MORTALITY ASSOCIATED WITH CHANGES IN RISK FACTORS AND TREATMENT UPTAKES IN ONTARIO BETWEEN 1994 AND 2005

    May 1, 2010, 00:00

  • PMH49 COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS AS ADJUNCTIVE THERAPY IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)

    May 1, 2010, 00:00

  • PMS46 STATISTICAL DATA ANALYSIS OF DIAGNOSIS RELATED GROUP 244- BONE DISEASES AND SPECIFIC ARTHROPATHIES WITH COMPLICATIONS

    May 1, 2010, 00:00

  • PMS61 ALTERNATIVE APPROACHES FOR ESTIMATING DRUG DOSING IN THE TREATMENT OF RHEUMATOID ARTHRITIS- THE CASE OF INFLIXIMAB

    May 1, 2010, 00:00

  • PCV67 EXPLORATORIES COST-CONSEQUENCE AND BUDGET IMPACT ANALYSIS OF SIROLIMUS-ELUTING STENT VS. ZOTAROLIMUSELUTING STENT FOCUSED ON THE RESTENOSIS AFTER DRUGELUTING STENT PLACEMENT UNDER THE PERSPECTIVE OF A BRAZILIAN PRIVATE PAYER

    May 1, 2010, 00:00

  • PCV100 INTERVENTIONS TO IMPROVE COMPLIANCE WITH LIPID LOWERING MEDICATIONS- A SYSTEMATIC REVIEW OF THE LITERATURE

    May 1, 2010, 00:00

  • PCV127 CARDIOVASCULAR DRUGS USAGE IN CROATIA AND SLOVENIA DURING THE NINE-YEAR PERIOD

    May 1, 2010, 00:00

  • PCASE6 THE FINANCIAL IMPACT OF A DAILY AVERAGE CONSUMPTION (DACON) ANALYSIS IN A US PHARMACY BENEFIT MANAGEMENT (PBM) COMPANY

    May 1, 2010, 00:00

  • PND28 CROSS CULTURAL EVALUATION OF THE SHORT FORM 8 ITEM PARKINSONS DISEASE QUESTIONNAIRE- RESULTS FROM AMERICA, CANADA, JAPAN, ITALY AND SPAIN

    May 1, 2010, 00:00

  • PMS67 TWO YEAR MAINTENANCE INFLIXIMAB DOSING AND ADMINISTRATION PATTERNS IN PATIENTS WITH RHEUMATOID ARTHRITIS

    May 1, 2010, 00:00

  • PCV148 RELATIONSHIP BETWEEN VENOUS THROMBOEMBOLISM AND HOSPITAL QUALITY

    May 1, 2010, 00:00

  • PCN133 A SUCCESSFUL ADOPTION OF PERSONALIZED MEDICINE- EXAMPLE OF KRAS MUTATIONAL ANALYSIS

    May 1, 2010, 00:00

  • PCV85 COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME (ACS) PATIENTS IN SPAIN

    May 1, 2010, 00:00

  • PRS3 THE PREVALENCE OF COMORBID CONDITIONS IN U.S. PATIENTS DIAGNOSED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    May 1, 2010, 00:00

  • PCV88 ECONOMIC EVALUATION OF THE USE OF REGADENOSON IN MYOCARDIAL PERFUSION IMAGING- CARDIOVASCULAR LABORATORY PERSPECTIVES

    May 1, 2010, 00:00

  • PCV81 DRUG-ELUTING STENTS VERSUS BARE-METAL STENTS FOR ACUTE MYOCARDIAL INFARCTION- AN ECONOMIC ANALYSIS APPROACH

    May 1, 2010, 00:00

  • PHP17 WHAT FACTORS PREDICT FAVORABLE MEDICARE COVERAGE?

    May 1, 2010, 00:00

  • PCN108 PSYCHOMETRIC VALIDATION OF A PATIENT QUESTIONNAIRE EVALUATING SATISFACTION WITH A DARBEPOETIN ALPHA PRE-FILLED DEVICE FOR SELF-INJECTION (ARANESPSURECLICKTMDEVICE), AND A HOME-SERVICE (2CARESERVICE) IN CHEMOTHERAPY-INDUCED ANAEMIC CA ...

    May 1, 2010, 00:00

  • PCN90 BORTEZOMIB IS COST-EFFECTIVE FOR FIRST-LINE TREATMENT OF MULTIPLE MYELOMA IN SWEDEN

    May 1, 2010, 00:00

  • PCN54 LOWER HEALTH CARE RESOURCE UTILIZATION ASSOCIATED WITH MANAGING NILOTINIB RELATED ADVERSE EVENTS IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS- EVIDENCE FROM A CLINICAL PRACTICE SETTING STUDY

    May 1, 2010, 00:00

  • PSY22 COST-EFFECTIVENESS OF STRATEGIES FOR DIAGNOSING HEPARIN-INDUCED THROMBOCYTOPENIA

    May 1, 2010, 00:00

  • PSY35 PERSISTENCE AND COMPLIANCE OF DEFEROXAMINE VERSUS DEFERASIROX IN MEDICAID PATIENTS WITH SICKLE-CELL DISEASE (SCD)

    May 1, 2010, 00:00

  • PCV92 ARE DOUBLE-BLIND, DOUBLE-DUMMY STUDIES SUITABLE FOR RESOURCE UTILISATION ANALYSES? AN EXAMPLE FROM A NEW ORAL ANTICOAGULANT FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) FOLLOWING ORTHOPAEDIC SURGERY

    May 1, 2010, 00:00

  • PMS28 COST-UTILITY ANALYSIS OF TUMOR NECROSIS FACTOR-ALPHA INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS USING A MARKOV MODEL

    May 1, 2010, 00:00

  • PGI12 FUNCTIONAL DYSPEPSIA DECREASE PRODUCTIVITY AND INCREASED MEDICAL COSTS

    May 1, 2010, 00:00

  • PMS53 UTILISATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN QUEBEC, CANADA- IS THERE A CHANGE IN THE PATIENT RISK PROFILE AFTER THE WITHDRAWAL OF ROFECOXIB?

    May 1, 2010, 00:00

  • PHP86 DEVELOPING GLOBAL ROAD MAPS FOR REIMBURSEMENT PROCESSES USED IN HEALTH TECHNOLOGY ASSESSMENT- PHARMACEUTICALS, MEDICAL DEVICES, AND DIAGNOSTICS

    May 1, 2010, 00:00

  • PDB60 GAPS IN MEDICAID COVERAGE AND THE RISK FOR HOSPITALIZATION AND MORTALITY AMONG INDIVIDUALS WITH DIABETES IN A MEDICAID PROGRAM

    May 1, 2010, 00:00

  • PHP116 ADVERSE DRUG REACTIONS OF 33 VARIETIES OF TRADITIONAL CHINESE MEDICINE INJECTIONS ON THE NATIONAL ESSENTIAL MEDICINES LIST (2004 EDITION) OF CHINA- AN OVERVIEW ON PUBLISHED LITERATURES

    May 1, 2010, 00:00

  • PND33 PREDICTORS OF PAIN MEDICATION SELECTION AMONG PATIENTS DIAGNOSED WITH FIBROMYALGIA

    May 1, 2010, 00:00

  • PMC33 THE TRANSLATION AND LINGUISTIC VALIDATION OF THE EQ-5D ELECTRONIC VERSION (EQ-5D EPRO)

    May 1, 2010, 00:00

  • PMH29 NATIONAL ESTIMATES OF THE INPATIENT BURDEN OF PEDIATRIC BIPOLAR DISORDER

    May 1, 2010, 00:00

  • PMC19 DIMENSIONS CHARACTERIZING GOOD HEALTH BY CHINESE IN CHINA

    May 1, 2010, 00:00

  • PSY20 COMPARISON OF DOSING PROFILES BETWEEN DULOXETINE AND PREGABALIN INITIATORS AMONG ELDERLY PATIENTS WITH FIBROMYALGIA

    May 1, 2010, 00:00

  • PCV103 A METHODOLOGY FOR USING CLAIMS DATA FROM ELECTRONIC PRESCRIBERS TO ASSESS FIRST FILL FAILURE RATE OF ANTIHYPERTENSIVE PRESCRIPTIONS

    May 1, 2010, 00:00

  • PMS44 USTEKINUMAB IMPROVES OVERALL SKIN RESPONSE AND HEALTH-RELATED QUALITY OF LIFE IN A SUBSET OF MODERATE TO SEVERE PSORIASIS PATIENTS WITH PSORIATIC ARTHRITIS- ANALYSIS OF PHOENIX 1 AND 2

    May 1, 2010, 00:00

  • PR4 ARE HEALTH STATES 'TIMELESS'? A TEST OF THE UTILITY INDEPENDENCE ASSUMPTION- COMPARING A REPEATED MEASURES DESIGN AND LATENT GROWTH MODELING

    May 1, 2010, 00:00

  • PRS9 COMPARISON OF CHRONIC BRONCHITIS IN ONTARIO, CANADA BETWEEN 2003 AND 2009

    May 1, 2010, 00:00

  • PSY16 MEDICAL SERVICES UTILIZATION AND EXPENDITURE OF OBESITY-RELATED DISORDERS IN TAIWANESE ADULTS

    May 1, 2010, 00:00

  • PMS75 METHODS FOR INTERPRETING TUMOR NECROSIS FACTOR (TNF) BLOCKER DOSING AND TREATMENT PATTERNS FROM PHARMACY AND PROFESSIONAL CLAIMS

    May 1, 2010, 00:00

  • PCN19 BREAST CANCER PATIENTS ARE TWICE AS LIKE TO DEVELOP ARTERIAL THROMBOEMBOLIC EVENTS AFTER DIAGNOSIS COMPARED TO CANCER-FREE WOMEN

    May 1, 2010, 00:00

  • PMS17 ESTIMATION OF COSTS OF HEALTH CARE FOR PEOPLE WITH RHEUMATOID ARTHRITIS FOR VARYING DEGREES OF DISABILITY AS MEASURED BY THE HEALTH ASSESSMENT QUESTIONNAIRE IN THE UNITED KINGDOM

    May 1, 2010, 00:00

  • PRS4 ESTIMATION OF MORTALITY RISKS ATTRIBUTABLE TO COMORBIDITY IN COPD

    May 1, 2010, 00:00

  • PGI3 PREVALENCE, COSTS AND SERVICES OF COMORBID CONDITIONS ASSOCIATED WITH FUNCTIONAL DYSPEPSIA

    May 1, 2010, 00:00

  • PSY48 THE VALUE TO PATIENTS OF TREATING PLAQUE PSORIASIS

    May 1, 2010, 00:00

  • PDB27 COST AND EFFECTIVENESS OF EDUCATIONAL STRATEGIES FOR THE CONTROL AND TREATMENT OF TYPE 2 DIABETES (DMT2) AND CARDIOVASCULAR RISK FACTORS (CVRF)

    May 1, 2010, 00:00

  • PCN119 USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE THE WILLINGNESS TO PAY FOR CANCER TREATMENT IN KOREA- A GENERAL POPULATION STUDY

    May 1, 2010, 00:00

  • PMH82 OUTCOMES OF SECOND GENERATION ATYPICAL ANTIPSYCHOTICS, FIRST GENERATION ANTIPSYCHOTICS AND ROUTINE OUTPATIENT BEHAVIORAL HEALTH SERVICES IN PREVENTING ARRESTS IN PERSONS WITH SEVERE MENTAL ILLNESS

    May 1, 2010, 00:00

  • PCV22 OUTCOMES ANALYSIS OF PROFILACTICAL HEALTH CARE PROGRAMS, BASED ON 'HEART VESSEL PROPHYLACTIC PROGRAM' FOR 40 AND 50 YEAR OLD RESIDENTS OF WROCLAW CITY

    May 1, 2010, 00:00

  • PDB47 IMPROVING OUTCOMES AND PRODUCTIVITY FOR EMPLOYEES WITH DIABETES

    May 1, 2010, 00:00

  • PHP67 COMPARISON OF DRUG TYPES IN INCIDENT REPORTS AMONG TEACHING HOSPITALS IN JAPAN

    May 1, 2010, 00:00

  • PMS9 COST BURDEN OF SECOND FRACTURE IN PATIENTS WITH COMMERCIAL INSURANCE

    May 1, 2010, 00:00

  • TR2 RECENT TRENDS IN EMPLOYER HEALTH CARE SPENDING BY DISEASE

    May 1, 2010, 00:00

  • PDB45 ASSOCIATION BETWEEN HEALTH INSURANCE PLAN TYPE AND MEDICATION POSSESSION RATIOS IN ADULT WORKING AGE PATIENTS WITH TYPE 2 DIABETES MELLITUS

    May 1, 2010, 00:00

  • PIH28 THE IMPACT OF MEDICARE PART D ON OUT-OF-POCKET DRUG EXPENDITURE OF THE ELDERLY

    May 1, 2010, 00:00

  • PMH72 CONCORDANCE OF COMPUTERIZED SELF-REPORT MEASURES OF DSM-IV-TR MOOD AND ANXIETY DISORDERS COMPARED TO GOLD STANDARD CLINICAL ASSESSMENTS IN PRIMAY CARE

    May 1, 2010, 00:00

  • PCN39 MORTALITY COSTS FROM GENITAL CANCERS IN MEN-UNITED STATES, 2004

    May 1, 2010, 00:00

  • PCV1 EFFECT OF BIVALIRUDIN ON CLINICAL OUTCOMES OF STEMI PATIENTS IN AN OBSERVATIONAL DATASET

    May 1, 2010, 00:00

  • PCV43 CLINICAL AND ECONOMIC IMPACT OF BIVALIRUDIN ON BLEEDING EVENTS IN HIGH RISK UNSTABLE ANGINA (UA)/NON-ST-ELEVATION MYOCARDIAL INFARCTION (NSTEMI) PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) IN FRANCE

    May 1, 2010, 00:00

  • PIH35 IMPACT OF PREVENTIVE TREATMENT WITH TITRATED DRY CRANBERRY EXTRACT IN A PATIENT SUFFERING FROM RECURRENT CYSTITIS

    May 1, 2010, 00:00

  • PSY56 INFLIXIMAB INDUCTION PATTERNS AND THE IMPACT ON MAINTENANCE THERAPY PATTERNS

    May 1, 2010, 00:00

  • PMH14 ALL-CAUSE TREATMENT DISCONTINUATION FOR OLANZAPINE COMPARED TO OTHER ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA- A META-ANALYSIS

    May 1, 2010, 00:00

  • PSS8 COST EFFICACY OF USTEKINUMAB IN TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN TURKEY

    May 1, 2010, 00:00

  • PM2 EFFECTS OF PRIMARY PROPHYLACTIC G-CSF USE AND DURATION OF USE ON NEUTROPENIA HOSPITALIZATIONS FOR ELDERLY BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY

    May 1, 2010, 00:00

  • PRS15 ECONOMIC BURDEN OF ANAPHYLAXIS IN THE UNITED STATES

    May 1, 2010, 00:00

  • ME3 IMPACT OF COST SHARING ON TREATMENT AUGMENTATION IN PATIENTS WITH DEPRESSION

    May 1, 2010, 00:00

  • PRS49 COMPARISON OF TWO METHODS FOR COVARIATE ADJUSTMENT WHEN ASSESSING HEALTH OUTCOMES IN THE U.S. HOSPITAL INPATIENT SETTING

    May 1, 2010, 00:00

  • PMS6 COMPARISON OF COST OF ALLOPURINOL VS FEBUXOSTAT AS A FIRST LINE TREATMENT FOR GOUT

    May 1, 2010, 00:00

  • PIN21 COST-EFFECTIVENESS OF THE ACIP RECOMMENDED ADULT IMMUNIZATION SCHEDULE IN THE US

    May 1, 2010, 00:00

  • PIH4 ASSESSMENT OF MATERNAL MORBIDITY DURING LABOR AND DELIVERY- EVALUATION OF LENGTH OF DELIVERY HOSPITALIZATION STAY OF WOMEN WITH PRE-EXISTING MEDICAL CONDITIONS

    May 1, 2010, 00:00

  • PMH70 OPIOID RELAPSE RATES AMONG A SAMPLE OF NEW BUPRENORPHINE-MEDICATION ASSISTED TREATMENT PATIENTS- RELATIONSHIP TO MEDICATION COMPLIANCE AT ONE YEAR

    May 1, 2010, 00:00

  • PRS17 COSTS TO TREAT COMMUNITY-ACQUIRED PNEUMONIA EPISODES IN US ADULTS AGED 50 YEARS AND OLDER BY AGE AND RISK

    May 1, 2010, 00:00

  • PCN86 COST-EFFECTIVENESS OF CETUXIMAB COMBINED WITH RADIOTHERAPY FOR PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK CANCER IN TAIWAN

    May 1, 2010, 00:00

  • PCV39 THE PUERTO RICO CARDIOVASCULAR RISK ESTIMATION STUDY (PRCARES)- AN EXPLORATORY ASSESSMENT OF NEW PATIENTS IN PHYSICIANS OFFICES

    May 1, 2010, 00:00

  • PIH3 RISK OF WEIGHT GAIN WITH THE USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI) AND ATYPICAL ANTIPSYCHOTICS (SGA) COMBINATION TREATMENT IN CHILDREN AND ADOLESCENTS

    May 1, 2010, 00:00

  • PMS27 THE COMMON PRACTICE OF ANTI-TNF PRESCRIPTION AND DISPENSING CONDITIONS

    May 1, 2010, 00:00

  • PSY38 HEALTH-RELATED FAMILY FUNCTIONING IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)-PATIENT INTERVIEWS SUPPORT SIX DOMAINS

    May 1, 2010, 00:00

  • PIH30 THE DETERMINANTS OF LIFE EXPECTANCY IN EASTERN MEDITERRANEAN COUNTRIES- AN ANALYSIS OF WORLD HEALTH ORGANIZATION (WHO) DATA

    May 1, 2010, 00:00

  • PCN74 COST-EFFECTIVENESS OF PROMOTORA LED HEALTH EDUCATION INTERVENTIONS TO INCREASE CERVICAL CANCER SCREENING AMONG LOW INCOME HISPANIC WOMEN

    May 1, 2010, 00:00

  • PMH32 IMPACT OF PERSISTENCE WITH BIPOLAR DISORDER TREATMENT REGIMES INVOLVING MOOD STABILIZERS, ANTIPSYCHOTICS, ANTIDEPRESSANT THERAPY

    May 1, 2010, 00:00

  • PCN77 COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ROMANIA

    May 1, 2010, 00:00

  • PHP42 THE ANNUAL HEALTH CARE EXPENDITURES PER CAPITA IN BRAZIL- A COMPARISON BETWEEN THE PUBLIC AND THE PRIVATE HEALTH CARE SYSTEMS

    May 1, 2010, 00:00

  • PCV124 ANTIHYPERTENSIVE PHARMACOTHERAPY-PHYSICIAN PERSPECTIVES AND PRESCRIBING PATTERNS IN THREE SOUTH INDIAN HOSPITALS

    May 1, 2010, 00:00

  • PGI14 DIRECT AND INDIRECT COSTS OF HEPATITIS C VIRUS (HCV)- COMPARISON OF NON-HCV, UNTREATED HCV, AND PEG-RBV TREATED HCV COHORTS

    May 1, 2010, 00:00

  • PCN87 THE POTENTIAL IMPACT OF USING CHANGES IN SERUM HER2 LEVELS TO INITIATE THERAPY CHANGE IN HER2 METASTATIC BREAST CANCER

    May 1, 2010, 00:00

  • PIH2 THE PREVALENCE AND USE OF POTENTIALLY INAPPROPRIATE MEDICATION IN ELDERLY POPULATION USING NATIONAL NURSING HOME SURVEY

    May 1, 2010, 00:00

  • PCN88 COST-EFFECTIVENESS OF LENOGRASTIM NEUTROPENIA DURATION IN ADULTS RECEIVING CHEMOTHERAPY FOR LEUKEMIA

    May 1, 2010, 00:00

  • PHP114 A TOOL FOR COST-MINIMIZATION STUDIES IN ANESTHESIA IN COLOMBIA

    May 1, 2010, 00:00

  • PHP5 UNCOVERING REASONS OF NON-COMPLIANCE IN EPRO STUDIES TO IMPROVE PRO DATA COLLECTION

    May 1, 2010, 00:00

  • PSY23 A COST-EFFECTIVENESS ANALYSIS OF CONVENTIONAL TREATMENT VERSUS BARIATRIC SURGERY FOR OBESE PATIENTS WITH TYPE-2 DIABETES AND HYPERTENSION AS COMORBIDITIES. PRELIMINARY RESULTS UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE

    May 1, 2010, 00:00

  • PCV72 COST-EFFECTIVENESS OF ROSUVASTATIN FOR THE PRIMARY PREVENTION OF VASCULAR EVENTS ACCORDING TO FRAMINGHAM RISK SCORE IN PATIENTS WITH AN ELEVATED C-REACTIVE PROTEIN

    May 1, 2010, 00:00

  • PCV69 COST-EFFECTIVENESS ANALYSIS OF THE USE OF ROSUVASTATIN IN PREVENTION OF VASCULAR EVENTS IN THE MEXICAN POPULATION BASED ON THE JUPITER STUDY

    May 1, 2010, 00:00

  • PRS1 A COMPARISON OF CLINICAL PROFILES, MEDICATION USE AND SYMPTOMOLOGY IN ASTHMA PATIENTS PRESCRIBED LOW/MODERATE DOSE FLUTICASONE PROPIONATE/SALMETEROL OR MODERATE/HIGH DOSE FLUTICASONE PROPIONATE

    May 1, 2010, 00:00

  • PMS69 DISPARITIES IN DISEASE MODIFYING ANTI-RHEUMATOID TREATMENT IN RHEUMATOID ARTHRITIS

    May 1, 2010, 00:00

  • PSY29 MODELING THE COST-EFFECTIVENESS OF BORTEZOMIB FOR THE INITIAL TREATMENT OF MULTIPLE MYELOMA IN THE UNITED STATES

    May 1, 2010, 00:00

  • PHP35 LOOKING FOR A COST-EFFECTIVENESS THRESHOLD IN KOREA

    May 1, 2010, 00:00

  • PRS5 COMORBIDITIES, QUALITY OF LIFE, AND HEALTH CARE ACCESS BY RISK COHORT CHARACTERISTICS OF PEOPLE CALCULATED USING FRAMINGHAM RISK PERCENT FROM THE US NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES)

    May 1, 2010, 00:00

  • RM1 COMPARATIVE PERFORMANCE OF RISK ADJUSTMENT MEASURES IN A SAMPLE OF COMMERCIALLY-INSURED PATIENTS UNDER AGE 65- TWO SIMPLE MEASURES OUTPERFORM CURRENT STANDARDS

    May 1, 2010, 00:00

  • PCV57 THE DIRECT MEDICAL COSTS OF STROKE IN KOREA

    May 1, 2010, 00:00

  • PMH27 ESCITALOPRAM (GENERIC DRUG) IN MAJOR DEPRESSIVE DISORDER (MDD) - BUDGET IMPACT ANALYSIS

    May 1, 2010, 00:00

  • PMH10 LONG-TERM OUTCOMES AFTER SWITCHING FROM TYPICAL ANTIPSYCHOTICS TO OLANZAPINE AMONG SCHIZOPHRENIA PATIENTS IN JAPAN

    May 1, 2010, 00:00

  • HT1 COMPARATIVE-EFFECTIVENESS VERSUS COST-EFFECTIVENESS- A COMPARISON OF THE FRENCH AND SCOTTISH APPROACHES TO SINGLE TECHNOLOGY ASSESSMENT (STA)

    May 1, 2010, 00:00

  • PGI27 OPEN VERSUS LAPAROSCOPIC PROCEDURES FOR CHOLECYSTECTOMY SURGERY- A COST-UTILITY ANALYSIS, UNDER THE BRAZILIAN PUBLIC PAYER PERSPECTIVE

    May 1, 2010, 00:00

  • PUK8 ERYTHROPOIESIS-STIMULATING AGENTS UTILIZATION AND COSTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS FROM TWO LARGE CLAIMS DATABASES

    May 1, 2010, 00:00

  • PRS11 PREDICTORS OF ANTIHISTAMINE PRESCRIPTION IN THE NATIONAL AMBULATORY POPULATION WITH ALLERGIC RHINITIS

    May 1, 2010, 00:00

  • PCN139 OPTIMISING MARKET ACCESS FOR ONCOLOGY DRUGS IN BRAZIL CHINA

    May 1, 2010, 00:00

  • PGI5 A META-ANALYSIS OF THE 5-HT3 RECEPTOR ANTAGONISTS USE IN POST-OPERATIVE NAUSEA AND VOMITING PROPHYLAXIS

    May 1, 2010, 00:00

  • PMS71 INDIRECT TREATMENT COMPARISONS OF BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS

    May 1, 2010, 00:00

  • PHP18 EVALUATION OF MEDICARE PART D PHARMACY AND MEDICAL UTILIZATION PATTERNS BY COVERAGE PHASE FOR COMMON CHRONIC DISEASES

    May 1, 2010, 00:00

  • PRS38 DRUG PRESCRIBING PATTERN IN AMBULATORY CARE SETTINGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN 2006-2007

    May 1, 2010, 00:00

  • PCN76 COST-EFFECTIVENESS OF WHITE BLOOD CELL GROWTH FACTOR USE AMONG ELDERLY NON-HODGKINS LYMPHOMA PATIENTS TREATED WITH CHEMOTHERAPY

    May 1, 2010, 00:00

  • PCN135 CONTROLLING THE COST OF CARE OF BREAST CANCER PATIENTS IN GERMANY USING CLINICAL PATHWAYS

    May 1, 2010, 00:00

  • PHP80 THE STATE OF HEALTH ECONOMICS AND PHARMACEOCONOMICS EVALUATION RESEARCH IN NIGERIA- A SYSTEMATIC REVIEW

    May 1, 2010, 00:00

  • PSS19 DEVELOPMENT OF A DECISION-ANALYTIC MODEL FOR GLAUCOMA PROGRESSION USING PATIENT LEVEL DATA FROM THREE LARGE RANDOMIZED CONTROLLED TRIALS

    May 1, 2010, 00:00

  • PCV24 A META-ANALYSIS OF EFFICACY AND SAFETY OF DALTEPARIN IN THE PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLIC DISEASE (VTE)

    May 1, 2010, 00:00

  • PMS7 COST ANALYSIS OF RECENTLY APPROVED AND OLDER ANTI-TNF BIOLOGIC AGENTS USED IN RHEUMATOID ARTHRITIS

    May 1, 2010, 00:00

  • PHP30 A DESCRIPTIVE EXAMINATION OF MARIJUANA AND COCAINE USE AMONG EMPLOYED PERSONS AND ITS ASSOCIATION WITH WORK DAYS SKIPPED AND HEALTH STATUS

    May 1, 2010, 00:00

  • PCV131 PREDICTORS OF COMPUTED TOMOGRAPHY USE FOR CORONARY ARTERY DISEASE PATIENTS IN EMERGENCY DEPARTMENTS IN THE UNITED STATES

    May 1, 2010, 00:00

  • PUK27 ERYTHROPOIESIS-STIMULATING AGENT DOSING AND HEMOGLOBIN TRENDS OVER TIME IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS

    May 1, 2010, 00:00

  • CV4 COMPARATIVE COST OF ABLATION IN ATRIAL FIBRILLATION PATIENTS STRATIFIED BY PROCEDURAL SUCCESS VERSUS FAILURE- IMPLICATIONS FOR RESOURCE UTILIZATION IN MEDICARE-AGED ABLATION CANDIDATES IN THE UNITED STATES

    May 1, 2010, 00:00

  • ME1 CLINICAL, ECONOMIC, AND HUMANISTIC BENEFITS OF A RHEUMATOID ARTHRITIS DISEASE THERAPY MANAGEMENT PROGRAM

    May 1, 2010, 00:00

  • PHP90 A DESCRIPTIVE STUDY OF PATIENTS ON FDA-CATEGORIZED INNOVATIVE DRUGS IN ANTICHOLESTEROL AND ANTIDIABETIC THERAPEUTIC CLASSES

    May 1, 2010, 00:00

  • PSY18 HEALTH CARE COSTS AND MEDICATION COMPLIANCE AMONG ELDERLY FIBROMYALGIA PATIENTS ON DULOXETINE VERSUS PREGABALIN

    May 1, 2010, 00:00

  • PMS34 CAPTURING DATA ON HEALTH CARE USE AND COSTS FOR PATIENTS WITH OSTEOARTHRITIS- AGREEMENT BETWEEN A PATIENT-COMPLETED QUESTIONNAIRE AND ADMINISTRATIVE RECORDS

    May 1, 2010, 00:00

  • PCV80 ECONOMIC ANALYSIS OF ENOXAPARIN IN COMPARISON WITH FONDAPARINUX IN THE TREATMENT OF DEEP-VEIN THROMBOSIS (DVT)

    May 1, 2010, 00:00

  • PCV40 HEALTH DISPARITIES IN MODIFIABLE RISK FACTORS FOR CORONARY HEART DISEASE- A COMPARISON OF APPALACHIAN TO NONAPPALACHIAN PORTIONS OF APPALACHIAN STATES

    May 1, 2010, 00:00

  • PCN82 COST COMPARISON OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE VERSUS PEMETREXED AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL CANCER IN GERMANY - AN UPDATED ANALYSIS

    May 1, 2010, 00:00

  • PHP33 REGIONAL INEQUALITIES IN THE UTILIZATION AND HEALTH INSURANCE REIMBURSEMENT OF SPA SERVICES IN HUNGARY

    May 1, 2010, 00:00

  • PCN41 HEALTH CARE COST OF BREAST CANCER- A CLAIMS DATA ANALYSIS

    May 1, 2010, 00:00

  • PIN24 AN INITIAL COST-EFFECTIVENESS ANALYSIS OF THE NEW 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV-I 3) VERSUS PCV-7 IN THE PUBLIC SECTOR OF HONG KONG

    May 1, 2010, 00:00

  • PGI25 PHARMACOECONOMIC ANALYSIS OF THE EFFECTS OF SECONDARY BACTERIAL RESISTANCE IN THE MULTI-DEPARTMENTAL HOSPITAL ON TREATMENT EFFICACY IN COMPLICATED ABDOMINAL INFECTIONS

    May 1, 2010, 00:00

  • PCN10 ESTIMATION OF G-CSF EFFECTIVENESS IN REDUCING NEUTROPENIA HOSPITALIZATION AMONG NON-HODGKINS LYMPHOMA (NHL) PATIENTS TREATED WITH ANTHRACYCLINE-BASED CHEMOTHERAPY

    May 1, 2010, 00:00

  • PDB73 QUALITY OF CARE FOR DIABETICS IN KARACHI PAKISTAN

    May 1, 2010, 00:00

  • PGI7 LOW PREVALENCE OF HEPATITIS C VIRUS (HCV) DIAGNOSIS IN US HEALTH CARE DATA

    May 1, 2010, 00:00

  • PCN24 OVERALL SURVIVAL AND DOCETAXEL TREATMENT CYCLES IN PATIENTS WITH METASTATIC PROSTATE CANCER - RESULTS FROM A US ONCOLOGY NETWORK

    May 1, 2010, 00:00

  • PSY30 COST-EFFECTIVENESS OF BARIATRIC SURGICAL PROCEDURES VERSUS NO TREATMENT FOR MORBID OBESITY

    May 1, 2010, 00:00

  • PMS10 THE INDIRECT COSTS ASSOCIATED WITH ABSENTEEISM OF WORKING ADULTS WITH RHEUMATOID ARTHRITIS- EVIDENCE FROM UNITED STATES NATIONAL SURVEY DATA

    May 1, 2010, 00:00

  • PMC9 DATA SCAFFOLDING- A PRAGMATIC APPROACH TO STRUCTURING A LITERATURE REVIEW SPREADSHEET TO MAXIMIZE INFORMATION, FACILITATE REVIEW AND SUPPORT ANALYSIS

    May 1, 2010, 00:00

  • PMS18 RHEUMATOID ARTHRITIS (RA) TREATMENT COSTS AMONG U.S. PATIENTS TREATED WITH INFUSED BIOLOGICS

    May 1, 2010, 00:00

  • PCV55 DIFFERENCE IN OUTCOMES MEASURES OF PATIENTS WITH VALVULAR AND NON-VALVULAR ATRIAL FIBRILLATION

    May 1, 2010, 00:00

  • PIH21 VALIDATION AND COMPARISON OF EUROQOL AND SHORT FORM 6D IN CHINESE CHRONIC PROSTATITIS PATIENTS

    May 1, 2010, 00:00

  • PGI33 CURRENT EVIDENCE REGARDING THE HEPATITIS C PATIENT EXPERIENCE

    May 1, 2010, 00:00

  • PCV113 IMPACT OF STROKE ETIOLOGY ON CARE NEED AND LONG-TERM OUTCOMES

    May 1, 2010, 00:00

  • PHP63 ADVERSE DRUG REACTIONS AND COST IMPLICATED- NEED FOR VIGILANT MONITORING

    May 1, 2010, 00:00

  • PDB55 THE IMPACT OF DIABETIC NON- SEVERE HYPOGLYCEMIC EPISODES ON FUNCTIONING AND DIABETES MANAGMENT- A 4 COUNTRY PERSPECTIVE

    May 1, 2010, 00:00

  • PND21 INTERIM ANALYSIS OF A LARGE ONGOING PHASE IV PROSPECTIVE OBSERVATIONAL COHORT STUDY (MDS ON BOTOX UTILITY-MOBILITY) OF BOTULINUM TOXIN TYPE A ON HEALTH UTILITY IN PATIENTS RECEIVING TREATMENT FOR APPROVED THERAPEUTIC INDICATIONS IN CA ...

    May 1, 2010, 00:00

  • PMH39 COST OF ILLNESS OF POST-TRAUMATIC STRESS DISORDER COMPARED WITH MAJOR DEPRESSIVE DISORDER

    May 1, 2010, 00:00

  • CASE3 THE VA TECHNOLOGY ASSESSMENT ADVISORY GROUP- INFORMING EVIDENCE-BASED POLICY RECOMMENDATIONS FOR ROBOTIC PROSTATECTOMY

    May 1, 2010, 00:00

  • PHP62 A MODEL TO ESTIMATE INCREASE IN REVENUE FROM IMPLEMENTING MEDICATION ADHERENCE MANAGEMENT SERVICES IN COMMUNITY PHARMACIES

    May 1, 2010, 00:00

  • PCN12 HORIZON SCANNING TO SUPPORT PRIORITY-SETTING FOR PROSPECTIVE COMPARATIVE EFFECTIVENESS RESEARCH (CER) IN CANCER GENOMICS

    May 1, 2010, 00:00

  • PCN89 COST EFFECTIVENESS ANALYSIS OF A CLINICAL PATHWAY FOR THE SURVEILLANCE OF HEPATOCARCINOMA IN COLOMBIA

    May 1, 2010, 00:00

  • Extended-Release Trospium Chloride Improves Quality of Life in Overactive Bladder

    Mar 1, 2010, 00:00

  • Use of Stabilized Inverse Propensity Scores as Weights to Directly Estimate Relative Risk and Its Confidence Intervals

    Mar 1, 2010, 00:00

  • Health State Survey-Derived Utilities in Cost-Utility Analysis—A Call to Action

    Mar 1, 2010, 00:00

  • Labeled versus Unlabeled Discrete Choice Experiments in Health Economics- An Application to Colorectal Cancer Screening

    Mar 1, 2010, 00:00

  • Crossing Borders- Factors Affecting Differences in Cost-Effectiveness of Smoking Cessation Interventions between European Countries

    Mar 1, 2010, 00:00

  • Cost-Effectiveness of Scheduled Maintenance Treatment with Infliximab for Pediatric Crohn's Disease

    Mar 1, 2010, 00:00

  • Cost-Effectiveness of Implantable Cardioverter-Defibrillators in Brazil- Primary Prevention Analysis in the Public Sector

    Mar 1, 2010, 00:00

  • Analysis of the Association between Metabolic Syndrome and Disease in a Workplace Population over Time

    Mar 1, 2010, 00:00

  • Understanding the Medical and Nonmedical Value of Diagnostic Testing

    Mar 1, 2010, 00:00

  • Reliability and Validity of a Chinese Version's Health-Related Quality of Life Questionnaire for Hepatitis B Patients

    Mar 1, 2010, 00:00

  • Value of Information Analyses of Economic Randomized Controlled Trials- The Treatment of Intermittent Claudication

    Mar 1, 2010, 00:00

  • Cost-Effectiveness of 21 Alternative Cervical Cancer Screening Strategies

    Mar 1, 2010, 00:00

  • In or Out? Income Losses in Health State Valuations- A Review

    Mar 1, 2010, 00:00

  • Health State Valuations of Patients and the General Public Analytically Compared- A Meta-Analytical Comparison of Patient and Population Health State Utilities

    Mar 1, 2010, 00:00

  • The Cost-Effectiveness of an Extended Course (12 + 12 Weeks) of Varenicline Compared with Other Available Smoking Cessation Strategies in the United States- An Extension and Update to the BENESCO Model

    Mar 1, 2010, 00:00

  • A Rapid-Response Economic Evaluation of the UK NHS Cancer Reform Strategy Breast Cancer Screening Program Extension via a Plausible Bounds Approach

    Mar 1, 2010, 00:00

  • Cost-Effectiveness of Using Recombinant Human Thyroid-Stimulating Hormone before Radioiodine Ablation for Thyroid Cancer- The Canadian Perspective

    Mar 1, 2010, 00:00

  • Erratum

    Mar 1, 2010, 00:00

  • Valuation of EQ-5D Health States in Poland- First TTO-Based Social Value Set in Central and Eastern Europe

    Mar 1, 2010, 00:00

  • Impact of Body Mass Index on the Incidence of Cardiometabolic Risk Factors in Ambulatory Care Settings over 5 Years or More

    Mar 1, 2010, 00:00

  • Impact of the 1997 Canadian Guidelines on the Conduct of Canadian-Based Economic Evaluations in the Published Literature

    Mar 1, 2010, 00:00

  • The Impact of Differences in EQ-5D and SF-6D Utility Scores on the Acceptability of Cost–Utility Ratios- Results across Five Trial-Based Cost–Utility Studies

    Mar 1, 2010, 00:00

  • Cost-Effectiveness of Screening and Optimal Management for Diabetes, Hypertension, and Chronic Kidney Disease- A Modeled Analysis

    Mar 1, 2010, 00:00

  • A Median Model for Predicting United States Population-Based EQ-5D Health State Preferences

    Mar 1, 2010, 00:00

  • Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses- An Industry Perspective- The ISPOR Drug Cost Task Force Report—Part V

    Jan 1, 2010, 00:00

  • A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukemia

    Jan 1, 2010, 00:00

  • Relationship between Adherence Level to Statins, Clinical Issues and Health-Care Costs in Real-Life Clinical Setting

    Jan 1, 2010, 00:00

  • Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses- An International Perspective- The ISPOR Drug Cost Task Force Report—Part VI

    Jan 1, 2010, 00:00

  • Beyond AWP … Way Beyond

    Jan 1, 2010, 00:00

  • What's in a Perspective?

    Jan 1, 2010, 00:00

  • Relationships among Self-Management, Patient Perceptions of Care, and Health Economic Outcomes for Decision-Making and Clinical Practice in Type 2 Diabetes

    Jan 1, 2010, 00:00

  • Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma

    Jan 1, 2010, 00:00

  • The Multinational Nature of Cost-Effectiveness Analyses Alongside Multinational Clinical Trials

    Jan 1, 2010, 00:00

  • Budget Impact Analysis of Thrombolysis for Stroke in Spain- A Discrete Event Simulation Model

    Jan 1, 2010, 00:00

  • Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses- A Societal Perspective- The ISPOR Drug Cost Task Force Report—Part II

    Jan 1, 2010, 00:00

  • Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses- Issues and Recommendations- The ISPOR Drug Cost Task Force Report—Part I

    Jan 1, 2010, 00:00

  • Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma

    Jan 1, 2010, 00:00

  • Erratum

    Jan 1, 2010, 00:00

  • Prevalence of Respiratory Syncytial Virus (RSV) Risk Factors and Cost Implications of Immunoprophylaxis to Infants 32 to 35 Weeks Gestation for Health Plans in the United States

    Jan 1, 2010, 00:00

  • Psychometric Development of the Individualized Retinopathy-Dependent Quality of Life Questionnaire (RetDQoL)

    Jan 1, 2010, 00:00

  • Patient Characteristics Impacting Health State Index Scores, Measured by the EQ-5D of Females with Stress Urinary Incontinence Symptoms

    Jan 1, 2010, 00:00

  • Relationship between Health-Related Quality of Life, Pain, and Functional Disability in Neuropathic Pain Patients with Failed Back Surgery Syndrome

    Jan 1, 2010, 00:00

  • Calibration of Disease Simulation Model Using an Engineering Approach

    Jan 1, 2010, 00:00

  • The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment- Modeled German Cost-Effectiveness Analysis

    Jan 1, 2010, 00:00

  • ISPOR Code of Ethics

    Jan 1, 2010, 00:00

  • Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses- A Managed Care Perspective- The ISPOR Drug Cost Task Force Report—Part III

    Jan 1, 2010, 00:00

  • A Methodology for Successfully Producing Global Translations of Patient Reported Outcome Measures for Use in Multiple Countries

    Jan 1, 2010, 00:00

  • Cost–Benefit Analysis of Preventing Nosocomial Bloodstream Infections among Hemodialysis Patients in Canada in 2004

    Jan 1, 2010, 00:00

  • Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses- Medicare, Medicaid and Other US Government Payers Perspectives- The ISPOR Drug Cost Task Force Report—Part IV

    Jan 1, 2010, 00:00

  • The Impact of Pharmaceutical Cost Containment Policies on the Range of Medicines Available and Subsidized in Finland and New Zealand

    Jan 1, 2010, 00:00

  • Instrumental Variables in Influenza Vaccination Studies- Mission Impossible?!

    Jan 1, 2010, 00:00

  • Pharmacoeconomic Guidelines and Their Implementation in the Positive List System in South Korea

    Nov 1, 2009, 00:00

  • Cost-Effectiveness Analysis of Oseltamivir for Influenza Treatment Considering the Virus Emerging Resistant to the Drug in Japan

    Nov 1, 2009, 00:00

  • Probabilistic Sensitivity Analysis- Be a Bayesian

    Nov 1, 2009, 00:00

  • Cost-Effectiveness Study Comparing Imatinib with Interferon-α for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Health-Care System Perspective (CPHSP)

    Nov 1, 2009, 00:00

  • A Survey of Knowledge on Diabetes in the Central Region of Thailand

    Nov 1, 2009, 00:00

  • Celebrating the 2nd Asia Special Issue- ISPOR Reaching a Six-Year Milestone in the Asia-Pacific Region

    Nov 1, 2009, 00:00

  • Use of Existing Patient-Reported Outcome (PRO) Instruments and Their Modification- The ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force R ...

    Nov 1, 2009, 00:00

  • Assessment of Total Economic Burden of Chronic Hepatitis B (CHB)-Related Diseases in Beijing and Guangzhou, China

    Nov 1, 2009, 00:00

  • The Current Capacity and Future Development of Economic Evaluation for Policy Decision-Making- A Survey among Researchers and Decision-Makers in Thailand

    Nov 1, 2009, 00:00

  • Reviewer Acknowledgment

    Nov 1, 2009, 00:00

  • Patient Experiences of Continuity of Cancer Care- Development of a New Medical Care Questionnaire (MCQ) for Oncology Outpatients

    Nov 1, 2009, 00:00

  • South Korean Time Trade-Off Values for EQ-5D Health States- Modeling with Observed Values for 101 Health States

    Nov 1, 2009, 00:00

  • A Concept Taxonomy and an Instrument Hierarchy- Tools for Establishing and Evaluating the Conceptual Framework of a Patient-Reported Outcome (PRO) Instrument as Applied to Product Labeling Claims

    Nov 1, 2009, 00:00

  • ISPOR Health Policy Council Proposed Good Research Practices for Comparative Effectiveness Research- Benefit or Harm?

    Nov 1, 2009, 00:00

  • Evidence-Based Decision-Making in Asia-Pacific with Rapidly Changing Health-Care Systems- Thailand, South Korea, and Taiwan

    Nov 1, 2009, 00:00

  • Using Economic Evaluation in Policy Decision-Making in Asian Countries- Mission Impossible or Mission Probable?

    Nov 1, 2009, 00:00

  • Evidence-Based Decision-Making on Medical Technologies in China, Japan, and Singapore

    Nov 1, 2009, 00:00

  • Evidence-Based Decision on Medical Technologies in Asia Pacific- Experiences from India, Malaysia, Philippines, and Pakistan

    Nov 1, 2009, 00:00

  • Relapse and Long-Acting Injectable Risperidone- A 1-Year Mirror Image Study with a National Claims Database in Taiwan

    Nov 1, 2009, 00:00

  • International Comparisons in Valuing EQ-5D Health States- A Review and Analysis

    Nov 1, 2009, 00:00

  • Costs and Health Utilities Associated with Extremely Preterm Birth- Evidence from the EPICure Study

    Nov 1, 2009, 00:00

  • Cost-Effectiveness of Long-Acting Risperidone Injection versus Alternative Atypical Antipsychotic Agents in Patients with Schizophrenia in China

    Nov 1, 2009, 00:00

  • Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly Controlled Type 2 Diabetes in South Korea

    Nov 1, 2009, 00:00

  • Good Research Practices for Comparative Effectiveness Research- Analytic Methods to Improve Causal Inference from Nonrandomized Studies of Treatment Effects Using Secondary Data Sources- The ISPOR Good Research Practices for Retrospective D ...

    Nov 1, 2009, 00:00

  • Comparative Analysis of Length of Stay, Total Costs, and Treatment Success between Intravenous Moxifloxacin 400 mg and Levofloxacin 750 mg among Hospitalized Patients with Community-Acquired Pneumonia

    Nov 1, 2009, 00:00

  • The Economic Value of Innovative Treatments over the Product Life Cycle- The Case of Targeted Trastuzumab Therapy for Breast Cancer

    Nov 1, 2009, 00:00

  • A Catalogue of EQ-5D Utility Weights for Chronic Diseases among Noninstitutionalized Community Residents in Korea

    Nov 1, 2009, 00:00

  • Growing Application of Pharmacoeconomics and Outcomes Research in Health-Care Decision-Making in the Asia-Pacific Region

    Nov 1, 2009, 00:00

  • Modeling the Cost-Effectiveness of Galantamine for Mild to Moderately Severe Alzheimer's Disease in Korea

    Nov 1, 2009, 00:00

  • A Time-Cost Augmented Economic Evaluation of Oral Deferasirox versus Infusional Dereroxmine for Patients with Iron Overload in South Korea

    Nov 1, 2009, 00:00

  • The Imperative to Improve

    Nov 1, 2009, 00:00

  • Good Research Practices for Comparative Effectiveness Research- Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources- The International Society for Pharmacoecon ...

    Nov 1, 2009, 00:00

  • The Impact of Health Literacy on Health-Related Quality of Life (HRQoL) and Utility Assessment among Patients with Rheumatic Diseases

    Nov 1, 2009, 00:00

  • Cost-Effectiveness of Using Clinical Risk Factors with and without DXA for Osteoporosis Screening in Postmenopausal Women

    Nov 1, 2009, 00:00

  • Reviewer Acknowledgments

    Nov 1, 2009, 00:00

  • An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer

    Nov 1, 2009, 00:00

  • Economic Evaluation of Universal Infant Vaccination with 7vPCV in Hong Kong

    Nov 1, 2009, 00:00

  • On Guidelines for Comparative Effectiveness Research Using Nonrandomized Studies in Secondary Data Sources

    Nov 1, 2009, 00:00

  • Psychometric Evaluation of the Diabetes Symptom Checklist-Revised (DSC-R)—A Measure of Symptom Distress

    Nov 1, 2009, 00:00

  • The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report

    Nov 1, 2009, 00:00

  • Valuation of the Economic Benefits of Human Papillomavirus Vaccine in Taiwan

    Nov 1, 2009, 00:00

  • Good Research Practices for Comparative Effectiveness Research- Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources- The ISPOR Good Research Practices for Retrospective Database Analy ...

    Nov 1, 2009, 00:00

  • Estimating Medical Expenditure Associated with Osteoporotic Hip Fracture in Elderly Korean Women Based on the National Health Insurance Claims Database 2002–2004

    Nov 1, 2009, 00:00

  • Impact of Diabetes Mellitus (DM) on the Health-Care Utilization and Clinical Outcomes of Patients with Stroke in Singapore

    Nov 1, 2009, 00:00

  • The Cost-Effectiveness of Bosentan in the United Kingdom for Patients with Pulmonary Arterial Hypertension of WHO Functional Class III

    Nov 1, 2009, 00:00

  • Establishing Optimal Requirements for Content Validity- A Work in Progress

    Nov 1, 2009, 00:00

  • Economic Impact on Health-Care Costs Related to Major Diseases Including HIV/AIDS due to Alcohol Drinking among Thai Populations

    Nov 1, 2009, 00:00

  • Psychometric Properties of a German Version of the “Satisfaction with Information about Medicines Scale” (SIMS-D)

    Nov 1, 2009, 00:00

  • Too Much Ado about Instrumental Variable Approach- Is the Cure Worse than the Disease?

    Nov 1, 2009, 00:00

  • Mapping the Cancer-Specific EORTC QLQ-C30 to the Preference-Based EQ-5D, SF-6D, and 15D Instruments

    Nov 1, 2009, 00:00

  • Evaluation of Cost-Utility of Varenicline Compared with Existing Smoking Cessation Therapies in South Korea

    Nov 1, 2009, 00:00

  • Evaluating Minimal Important Differences for the FACT-Melanoma Quality of Life Questionnaire

    Nov 1, 2009, 00:00

  • PCN118 COST EFFECTIVENESS OF CETUXIMAB IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER- DESCRIPTION OF A NICE SUBMISSION

    Oct 1, 2009, 00:00

  • PCN30 IMPACTO EMOCIONAL EN UN GRUPO DE MUJERES MEXICANAS CON DIAGNSTICO DE VPH Y NEOPLASIA INTRACERVICAL (NIC-II/III)

    Oct 1, 2009, 00:00
  • «
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140 (current)
  • »